EQS-Adhoc: General partner of CompuGroup Medical SE & Co. KGaA plans dividend increase
EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Dividend
General partner of CompuGroup Medical SE & Co. KGaA plans dividend increase
20-Feb-2024 / 20:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
General partner of CompuGroup Medical SE & Co. KGaA plans dividend increase
Against the background of the stable financial and earnings position the general partner of CompuGroup Medical SE & Co. KGaA (CGM) intends to sustainably increase the dividend payment to a higher level. Therefore, the general partner plans to propose to the Annual General Meeting to increase the dividend per dividend bearing share to EUR 1.00 for the financial year 2023, compared to a dividend of EUR 0.50 per share for the financial year 2022.
The proposed dividend increase will be on the agenda of the Supervisory Board after the final financial statements for the financial year 2023 are available.
A dividend payment based on the final dividend proposal of the general partner and the Supervisory Board for the financial year 2023 is subject to the approval of the Annual General Meeting as well as further legal requirements.
CompuGroup Medical SE & Co. KGaA will publish the full Annual Report for the financial year 2023 as planned on March 28, 2024.
End of Inside Information
20-Feb-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
CompuGroup Medical SE & Co. KGaA |
|
Maria Trost 21 |
|
56070 Koblenz |
|
Germany |
Phone: |
+49 (0)160 3630362 |
Fax: |
+49 (0)261 8000 3200 |
E-mail: |
[email protected] |
Internet: |
www.cgm.com |
ISIN: |
DE000A288904 |
WKN: |
A28890 |
Indices: |
SDAX, TecDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1841405 |
|
End of Announcement |
EQS News Service |
1841405 20-Feb-2024 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
582,38 |
717,02 |
745,81 |
837,26 |
1.025,32 |
1.129,74 |
1.187,66 |
EBITDA1,2 |
128,44 |
187,84 |
178,13 |
197,48 |
213,39 |
216,35 |
229,76 |
EBITDA-Marge3 |
22,05 |
26,20 |
23,88 |
23,59 |
20,81 |
19,15 |
|
EBIT1,4 |
90,07 |
143,23 |
115,27 |
121,77 |
102,68 |
104,03 |
98,00 |
EBIT-Marge5 |
15,47 |
19,98 |
15,46 |
14,54 |
10,01 |
9,21 |
8,25 |
Jahresüberschuss1 |
31,74 |
96,34 |
66,15 |
73,42 |
69,03 |
74,12 |
46,87 |
Netto-Marge6 |
5,45 |
13,44 |
8,87 |
8,77 |
6,73 |
6,56 |
3,95 |
Cashflow1,7 |
85,82 |
136,35 |
110,50 |
149,93 |
165,27 |
145,03 |
179,53 |
Ergebnis je Aktie8 |
0,63 |
1,92 |
1,33 |
1,40 |
1,30 |
1,40 |
0,88 |
Dividende8 |
0,35 |
0,50 |
0,50 |
0,50 |
0,50 |
0,50 |
0,35 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
CompuGroup Medical |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A28890 |
14,040 |
Halten |
754,43 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
12,00 |
34,38 |
0,35 |
12,02 |
KBV |
KCV |
KUV |
EV/EBITDA |
1,23 |
4,20 |
0,64 |
6,24 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,50 |
1,00 |
7,12 |
22.05.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
08.05.2024 |
08.08.2024 |
07.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-6,27% |
-45,19% |
-62,96% |
-61,28% |
|
|